<DOC>
	<DOCNO>NCT00807144</DOCNO>
	<brief_summary>The current anti−rejection drug regime kidney transplant recipient use West London Renal &amp; Transplant Centre ( WLRaTC ) consist induction therapy potent monoclonal antibody Campath 1−H ( Alemtuzumab ) follow long−term maintenance Calcineurin inhibitor Tacrolimus The recent development ( license UK ) extended−release , daily formulation Tacrolimus hold promise simple drug regimes patient . In context current successful use Tacrolimus monotherapy maintenance Campath 1−H induction , extended−release Tacrolimus formulation enable u offer regime long−term immunosuppressive treatment patient need single drug , take day . The investigator wish ass efficacy regime structure comparison current protocol .</brief_summary>
	<brief_title>Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction Kidney Transplantation</brief_title>
	<detailed_description>1 . Purpose Study : The current immunosuppressive regime use anti−rejection therapy kidney transplantation West London Renal &amp; Transplant Centre Imperial College Healthcare NHS Trust consist induction therapy Campath 1−H ( Alemtuzumab ) 1 week course steroid follow maintenance mono-therapy standard−release ( twice daily ) Tacrolimus ( Prograf ) . This study design compare cost outcomes regime one extended−release ( daily ) Tacrolimus ( Advagraf ) use place standard−release Tacrolimus . 2 . Study Type : Phase IV 3 . Study Design : Prospective , randomise , control , open study . Patients randomize 1:1 standard extended−release Tacrolimus arm . Study entry stratify live donor v decease donor transplant . The total recruitment target 100 patient ( 50 standard release/50 extend release ) . 4 . Study Description : Patients randomise receive either Prograf Advagraf prior transplantation . Other take extra blood sample time routine clinical visit , participant receive identical in−patient out−patient management patient undergo kidney transplantation standard protocol . Patients study ask complete short Health−Related Quality Life questionnaire ( SF−36 ) transplantation 1 year post transplant . They also ask complete Medication Adherence Rating Score 3 , 6 , 12 month post−transplant .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Live donor kidney transplant recipient heartbeatingDeceased donor kidney transplant recipient Patients suitable induction therapy Alemtuzumab Recipients Nonheartbeating decease donor kidney transplant Recipients simultaneous kidney/pancreas transplant ABO incompatible/desensitized transplant recipient Positive flow crossmatch/desensitized transplant recipient Patients heavy prior exposure myelosuppressive therapy Patients previous malignancy Patients HIV , HepatitisC , HepatitisB infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>Rejection</keyword>
	<keyword>Adherence</keyword>
	<keyword>Quality life</keyword>
</DOC>